Prelude Therapeutics | 4:持股变动声明-高管 Huang Jane
Prelude Therapeutics | 4:持股变动声明-董事 BAKER BROS. ADVISORS LP
Prelude Therapeutics | 4:持股变动声明-董事 Bonita David P
Prelude Therapeutics | 4:持股变动声明-董事 Sandor Victor
Prelude Therapeutics | 4:持股变动声明-董事 FRIEDMAN PAUL A
Prelude Therapeutics | 4:持股变动声明-董事 Dier Mardi
Prelude Therapeutics | 4:持股变动声明-董事 Babler Martin
Prelude Therapeutics | 4:持股变动声明-高管 Lim Bryant David
Prelude Therapeutics | 4:持股变动声明-高管 Huang Jane
Prelude Therapeutics | 4:持股变动声明-高管 Scherle Peggy
Prelude Therapeutics | 4:持股变动声明-高管 Lim Bryant David
Prelude Therapeutics | 4:持股变动声明-高管 Chardonnet Laurent
Prelude Therapeutics | 4:持股变动声明-高管 Combs Andrew
Prelude Therapeutics | 4:持股变动声明-高管 Huang Jane
Prelude Therapeutics | 4:持股变动声明-高管 Vaddi Krishna
Prelude Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-UBS Group AG (for the benefit and on behalf of the UBS Asset(0%)
Prelude Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Deerfield Mgmt, L.P.(9.85%),Deerfield Management Company, L.P.(9.85%)等
Prelude Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Krishna Vaddi(11.1%)
Prelude Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(0.630%),Abigail P. Johnson(0.630%)
Prelude Therapeutics | 4:持股变动声明-高管 Huang Jane
暂无数据